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Why is this study important?
Atherosclerotic stenosis of the major intracranial arteries
is one of the most common causes of stroke worldwide. It
causes 30% to 50% of strokes in Asians and 8% to 10% of
strokes in North American Caucasians. Intracranial
atherosclerosis preferentially affects Asians, Hispanics, Far
East Asians and Blacks. 
Patients with a recent transient ischaemic attack (TIA) or
stroke and severe stenosis (70 to 99% of the diameter of a
major intracranial artery) are at particularly high risk for
recurrent stroke in the territory of the stenotic artery
(approximately 23% at 1 year).
There are two treatment strategies that have emerged for
the management of high-risk patients: aggressive medical
therapy (combination anti-platelet therapy and intensive
management of risk factors) and percutaneous Tran's
luminal angioplasty and stenting (PTAS).
There is uncertainty regarding the safety and efficacy of
aggressive medical management alone as compared with
aggressive medical management plus PTAS with the use
of the Wingspan stent system. For this reason this trial
(SAMMPRIS) was the first trial started in November 2008
to compare the two treatment options in high risk
patients with intracranial arterial stenosis. 
Who were the participants?
SAMMPRIS was an investigator-initiated, randomized,
double-blind, multi-center clinical trial funded by the
National Institute of Neurological Disorders and Stroke
and conducted at 50 sites in the United States. Population
of interest included both inpatients and outpatients at the
participating sites. Patients were recruited if they had a
TIA or non-disabling stroke within 30 days before
enrollment, attributed to angiographically verified
stenosis of 70 to 99% of the diameter of a major
intracranial artery.
A total of 451 patients underwent randomization, 227
were assigned to the medical-management group and
224 to the PTAS group. There were no significant
differences between the two groups with respect to any
of the baseline characteristics of the patients.
What was the intervention?
Medical management was identical in the two groups and
consisted of aspirin, at a dose of 325 mg per day;
clopidogrel, at a dose of 75 mg per day for 90 days after
enrollment; management of the primary risk factors
(elevated systolic blood pressure and elevated low-
density lipoprotein [LDL]cholesterol levels); and
management of secondary risk factors (diabetes, elevated
non-high-density lipoprotein [non-HDL] cholesterol
levels, smoking, excess weight, and insufficient exercise)
with the help of a lifestyle modification programme. The
target for systolic blood pressure of less than 140 mm Hg
(<130 mm Hg in the case of patients with diabetes) and
an LDL cholesterol level of less than 70 mg per deciliter
(1.81 mmol per liter).The aspirin, clopidogrel, one drug
from each major class of antihypertensive agents,
rosuvastatin, and the lifestyle programme were provided
to the study patients.
PTAS were performed by neurointerventionists who were
selected by a committee of experienced
neurointerventionists. Patients who were randomly
assigned to PTAS were required to undergo the procedure
within 3 business days after randomization. Patients who
were not taking clopidogrel at a dose of 75 mg each day
for at least 5 days before PTAS were given a 600-mg
loading dose of clopidogrel between 6 and 24 hours
before PTAS.
On April 5, 2011, the trial's independent data and safety
monitoring board recommended that enrollment be
stopped because of safety concerns regarding the risk of
per procedural stroke or death in the PTAS group and
because futility analyses indicated that there was virtually
no chance that a benefit from PTAS would be shown by
the end of the follow-up period if enrollment continued.
Although follow-up of patients is ongoing, the clinical
importance of these findings mandated the reporting of
the current results.
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What was the outcome?
The primary end point the 30-day rate of stroke or death
was 14.7 %( 33 patients) in the PTAS group (nonfatal
stroke, 12.5%; fatal stroke, 2.2%) and 5.8% (13 patients) in
the medical-management group (nonfatal stroke, 5.3%;
non-stroke-related death, 0.4%) (p<0.002). Beyond 30
days, stroke in the same territory occurred in 13 patients
in each group. Currently, the mean duration of follow up
which is ongoing, is 11.9 months. 
The probability of the occurrence of a primary end-point
event over time differed significantly between the two
treatment groups (p<0.009), with 1-year rates of the
primary end point of 20.0% in the PTAS group and 12.2%
in the medical-management group. In secondary end
points the rates of any stroke and of any major
hemorrhage 14.1% vs. 22.3%) were significantly (p<0.03)
higher in the PTAS group than in the medical-
management group. The difference between the two
groups in the rate of death or any stroke (16.3% vs. 23.2%)
was not significant (p<0.06). in terms of myocardial
infarction there was no significant difference between
two groups (3.1% vs. 2.2% p<0.60). 
What were the conclusions?
In patients with intracranial arterial stenosis, aggressive
medical management was superior to PTAS with the use
of the Wingspan stent system, both because the risk of
early stroke after PTAS was high and because the risk of
stroke with aggressive medical therapy alone was lower
than expected. 
How does this impact our clinical practice?
Intracranial atherosclerosis is an important cause of
ischaemic stroke in our population. In our country where
there are significant financial constraints and lack of
expertise in neuro intervention, this study showed
aggressive medical management plays an important role
in preventing recurrent stroke form intracranial stenosis.
Clinicians are advised to actually strive to achieve medical
targets in their patients with intracranial stenosis.
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